CAMBRIDGE

Cambridge University Press
0521783496 - Stages and Pathways of Drug Involvement: Examining the Gateway Hypothesis
Edited by Denise B. Kandel
Index
More information

Index

Add Health data set, 266–267
addiction, and animal models, 337–339. *See also* reinforcement
Adolescent Alcohol Prevention Trials (AAPT), 256–257, 266–267
adolescents and adolescence. *See* development; *specific topics*
age of onset: and approaches to prevention, 119–124; and basic model of progression, 70–73, 208–209, 213, 217–222, 226; and development trajectories, 29–38; and historical variations, 105–109; measures of, 24–25; as predictor of abuse and dependence, 22; and progression, 78–79, 82–84; and sequencing, 26–29. *See also* birth cohorts; children; initiation
aggression, and initiation of drug use in adolescents, 175–176
alcohol and alcohol abuse: and age of first use as predictor of drug abuse and dependence, 22, 24, 26–29; and attentional processes, 299, 300; and basic model of progression, 70–73; and behavioral features of progression, 78–87; and caffeine use as risk factor, 255; and cross-sensitization, 325; and diagnostic criteria for dependence, 25–26; and feeding behaviors in animal models, 298; and GABA neurons, 320–321; and gender differences in sequences of progression, 73–76, 199–204, 214–216; and growth curve modeling of progression, 232–240, 241–245, 246–248; interaction with early concurrent use of cigarettes, 300–301; latent transition analysis of progression, 256–268; and life skills training approach to prevention, 125–126, 128, 129–130; and locomotion in animal, 305–306; and measure of use intensity, 25; and multicommunity-based prevention program, 153; and parametric event sequence analysis, 206–211, 218–222; predictors of initiation of use in adolescents, 168–169; and prevention studies, 120, 162–164; and progression to hard drug use in inner-city New York, 98–110; race and patterns of progression, 204–206, 214–216; reasons for experimentation with, 291, 292; and reinforcement, 348; and relapse, 349; and sequence of progression, 20–21, 225–226; and social norms of acceptability and

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521783496 - Stages and Pathways of Drug Involvement: Examining the Gateway Hypothesis
Edited by Denise B. Kandel
Index
More information

alcohol and alcohol abuse (*cont.*)
harm, 42–43, 44, 46–63; and stress in animal models, 301; and substance-specific progression, 117–118; substitutability and progression, 190–191, 196; and transition diagrams, 97–98; and use trajectory as predictor of abuse or dependence, 32, 33–38
American Psychiatric Association. *See* DSM-IV
amphetamines: and cross-sensitization in animal models, 324; and multicommunity-based prevention program, 145, 148, 150–154; and reinforcement, 340, 342; stress and self-administration of in animal models, 303
animal models: and contributions to study of drug abuse, 289–290; and neurobiology of addiction, 337–352; potential of for examination of Gateway Hypothesis, 294–308; and research on prevention, 293–294, 308; and research on progression, 8; and studies of behavior, health, and drug use, 292–293
antisocial behavior, and initiation of drug use in adolescents, 164–165, 167, 168, 170, 172–173, 176–177
Anzalone, D., 224
appetitive behaviors, and animal models of drug abuse, 297–299
Arrestee Drug Abuse Monitoring Program (ADAM), 94–97, 100, 101*f*, 102, 103, 105, 106
Ary, D. V., 162
assertiveness, and life skills training program, 130–132, 133, 134
association: and causality, 4, 283–284, 366, 370–371; conceptual distinction between sequencing and, 4, 66–67, 187–191, 213–216, 276; of lifetime use between alcohol and marijuana, 76; log linear models and strength of, 69; and parametric event sequence analysis of progression, 206–211, 217–222; and parsing of Gateway Hypothesis, 369; and stages of progression, 188, 270, 274–277; and substitutability of substances in initiation of drug use, 190–191; use of term, 4
attentional effects, and animal models of drug use, 299–301
attention deficit hyperactivity disorder (ADHD), 299

barbiturates, and reinforcement, 343
Barnes, G. M., 6
Bates, M. E., 22
Bayesian information criteria (BIC), 198, 218
behavior: animal models and studies of health, drug use, and, 292–293; and features of drug histories associated with progression, 78–87; psychostimulants and sensitization, 321. *See also* aggression; antisocial behavior; appetitive behaviors; delinquency
Bentler, P. M., 224, 235, 270, 271–272, 272–273, 274, 275, 276, 281, 284
benzodiazepines, and reinforcement, 343
Biglan, A., 160–161, 162
biological factors: and animal models of drug use and abuse, 292–293, 295; and marijuana as gateway for cocaine, 265. *See also* neurobiology
biopsychosocial views, of drug use sequences, 223
birth cohorts: and differences in sequences of drug use, 367; and parametric event sequence analysis of progression, 213; and progression to hard drug use in inner-city New York, 102–105, 107*t*. *See also* age of onset
Black, C., 162
body weight, and animal models for appetitive behaviors, 297–299
bonding, to mother and social norms of substance use, 53, 62
Brown, B. B., 90

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521783496 - Stages and Pathways of Drug Involvement: Examining the Gateway Hypothesis
Edited by Denise B. Kandel
Index
More information

caffeine: as risk factor for alcohol use, 255; and sensitization in animal models, 325–326
California, and study of alcohol use in adolescents, 257
cannabinoids, and dopamine, 321. *See also* marijuana; THC
catecholamine, and response to stress, 303
causation and causality: and current limitations on establishment of, 283–284; as fundamental issue in research on Gateway Hypothesis, 8–9, 290–292, 359–371; use of term, 4
Chen, K., 21, 224, 225
children: and self-report studies, 289, 292; and social norms of substance use, 45–46. *See also* age of onset
China, and tobacco use, 227
Chou, S. P., 22
cigarettes: and age of first use as predictor of drug abuse or dependence, 26–29; appetitive behaviors and body weight, 297–299; and basic model of progression, 70–73; and behavioral features of progression, 78–87; and behavioral influences on use of, 160–164; and gender differences in sequences of progression, 73–76, 199–204, 214–216; growth curve modeling and role of in drug use progression, 232–246; and latent transition analysis of initiation, 257–268; and life skills training approach to prevention, 125, 126–127,128, 129–130; and multicommunity-based prevention program, 153; and parametric event sequence analysis, 206–211, 218–222; and predictors of initiation, 164–170; and progression to hard drug use in inner-city New York, 98–110; race and patterns of progression, 204–206, 214–216; reasons for initiation of, 290, 291, 292; and sequential model of drug use progression, 20–21, 224–227; and social norms of acceptability and harm, 42–43, 44, 46–63; and stress, 301–304; and studies of prevention, 120; and substance-specific progression, 117–118; substitutability and progression, 190–191, 196; and transition diagrams, 97–98; and use trajectory as predictor of drug abuse or dependence, 32, 33–38. *See also* nicotine and nicotine dependence
Cliff, N., 271
Clogg, C. C., 279
CNS depressants, and attentional processes, 300
cocaine: and attentional processes, 301; and basic model of progression, 70–73; and behavioral features of progression, 78–87; and cross-sensitization, 323, 325, 326; and daily use, 94; and dopamine levels, 321; and gender differences in sequences of progression, 73–76, 199–204, 214–216; and latent transition analysis of progression, 257–268; marijuana use and initiation of, 67; and parametric event sequence analysis, 206–213, 218–222; and progression to hard drug use in inner-city New York, 109; race and patterns of progression, 204–206, 214–216; and reinforcement, 340, 345, 348, 350, 351; and relapse, 349; and reward thresholds, 346*f*; self-administration and social interactions in animal models, 304; and sensitization, 327–328, 328–330; and studies of order of progression, 6
coercive interactions, and behavioral influences on problem behavior in adolescents, 175
Collins, L. M., 7, 227, 246, 254, 255, 258, 260, 270, 271, 272, 273, 274, 276, 277–280, 281–282, 283
communication, and life skills training program, 123
comparative fit index (CFI), 235
conflict, and parental influences on problem behavior in children, 171

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521783496 - Stages and Pathways of Drug Involvement: Examining the Gateway Hypothesis
Edited by Denise B. Kandel
Index
More information

contextualism, and behavioral influences on smoking and problem behavior in adolescents, 158, 165, 176, 178
contingency table model, and latent transition analysis, 267
coping skills, and life skills training program, 123
Cornell University Medical College, 122, 124
corticosterone, and response to stress, 303
corticotropin-releasing factor (CRF) function, and reinforcement, 347–348
craving, and neurobiological substrates, 348–349
cross-lagged autoregressive models, and role of cigarettes in drug use progression, 228, 235–237, 241–242
cross-sectional studies, and evidence for Gateway Hypothesis, 5
cross-sensitization, and animal models, 323–325
cross-validation study, of role of cigarettes in drug use progression, 240–249
culture: and behavioral features of progression, 87; and determination of gateway order of substances, 92, 265, 370. *See also* social context; social norms
cyclic aminophosphate response-element binding protein (CREB), 348

Dawson, D. A., 22
decision making, and life skills training program, 123
de Leeuw, J., 279
delinquency: and behavioral influences on initiation of drug use, 177; and developmental sequences of drug use, 367
Dent, V. W., 271
dependence: predicted by use trajectories, 29–35; and stage of drug use, 80–82
development: and drug involvement, 68–78; and life skills training program, 130–134; and perspectives on progression, 116–119, 226; and sequence proposition in Gateway Hypothesis, 367–368; and use trajectories based on age of onset and intensity, 29–35
developmental trajectories, 19
Dishion, T. J., 173–174
Dolcini, M. D., 90
Donaldson, S. I., 45
Donovan, J. E., 7, 225, 271
dopamine system: and caffeine, 326; and cannabinoids, 321; and reinforcement, 340, 342–344, 352; and self-administration of drugs in animal models, 303, 321; and theory of genetic variations and drug use sequences, 223
drug abuse: definition of, 319; measures of, 25–26; pharmacological characteristics of, 320–321; and sensitization, 321. *See also specific substances*
drug dependence: measures of, 25–26; and reinforcement, 338–339; and stages of drug use, 80–82
drug discrimination, and animal models, 306
drug-related information and skills, 123–124
Drug Use Forecasting (DUF) Program. *See* Arrestee Drug Abuse Monitoring Program
DSM-IV (American Psychiatric Association, 1994), and diagnostic criteria for drug abuse and drug dependence, 25, 68
Duncan, S. C., 173, 240, 244, 245, 246
Duncan, T. E., 162, 173, 175, 240, 244, 245, 246
DuPont, R., 3
dysphoria, and withdrawal, 352

Eccles, J. S., 91
economic factors, and operant conditioning paradigms in animal models, 294

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521783496 - Stages and Pathways of Drug Involvement: Examining the Gateway Hypothesis
Edited by Denise B. Kandel
Index
More information

Ellickson, P. L., 225, 227
emotions, withdrawal and negative, 345
ethanol, and animal models: and attentional processes, 300–301; and cross-sensitization, 324; and reinforcement, 343–344, 350; and reward thresholds, 346*f*; and stress, 303
ethics, and research on drug use in children, 291
ethnicity: and differences in sequences of progression, 76–78, 215; and initiation of alcohol and tobacco use, 55, 56, 59; and log linear analysis of progression, 204–206. *See also* race
etiology, of drug use: and association, 369; and causation, 370
extended amygdala, and reinforcement, 340, 349–351

face valid animal models, 295–297
family: and behavioral influences on adolescent smoking, 165; and initiation of tobacco use, 59; management practices and initiation of alcohol and marijuana use, 62; as protective factor for progression, 54–62; and social influences on drug use, 121. *See also* parents and parenting
Family Environment Scale, 165
Faraday, M. M., 306
Faust, R., 225, 271
feeding behaviors, and alcohol, 298
Fendrich, M., 91
fentanyl, and animal models of self-administration, 296, 302, 304
Flaherty, B. P., 227, 246
Fleming, R., 224
follow-up study, of life skills training program, 129–130
forward telescoping, 98
fos-related antigens (FRAs), 348
frequency, of drug use: and impact of national levels on the behavior of individual users, 83–87; and life skills training approach to prevention, 126–127; and progression, 79–80, 84, 117. *See also* intensity
functional contextualism, and relations between behavior and environment, 159

GABA (gamma-aminobutynic acid): and alcohol, 320–321; receptor complexes and reinforcement, 341*f*, 343
Gateway drug: caffeine as, 325–326; concept and definition of, 7–8; "hard" drugs as, 328–330; methylphenidate as, 326–328; use of term, 3
Gateway Hypothesis: and animal models for neurobiology of addiction, 337–352; and animal models for sensitization, 318–330; and association proposition, 4, 283–284, 366, 369; causation and causal proposition, 8, 366, 369–371; cigarette use and growth curve modeling for analysis of progression, 223–249; and component propositions, 365–367; concepts and measurement of stages of progression, 270–284; criticisms of, 224–227; development of concept, 3–7; fundamental issues in research on, 7–10; future of research on, 371–372; gender and race differences in progression, 187–222; intervention efforts and influences on development of problem behavior, 158–179; and latent transition analysis, 254–268; parsing of, 365–367; prevention of onset and progression of drug use in adolescents, 115–135; prevention programs and applications of, 139–154; progression and hard drug use in New York City, 90–110; and sequence proposition, 367–368; and sequencing, age of onset, and use trajectories as predictors of future drug abuse, 19–38; social norms and transitions in substance use, 42–63; and stages of drug involvement, 65–87, 118–119; and validity criteria, 4; and value of animal models, 289–308

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521783496 - Stages and Pathways of Drug Involvement: Examining the Gateway Hypothesis
Edited by Denise B. Kandel
Index
More information

gender: and animal models of drug effects, 295, 307; and behavioral influences on problem behavior in adolescents, 175; and growth curve models of role of cigarette smoking in drug use progression, 239, 241–245; and log linear models of progression, 199–204, 214–216; and parametric event sequence analysis of initiation, 208–209*t*, 211, 213, 217–222; and progression to hard drug use in inner-city New York, 107*t*; and risk of marijuana initiation, 59; and sequences of progression, 73–76; and stress-drug self-administration relationship, 302
genetic variations: drug use sequences and theory of, 223; genotype and animal model studies, 295, 306–307
Goldstein, P. J., 91
Golub, A., 10, 20–21, 65, 91, 92, 98
Goodman, L. A., 271, 279, 280
Graham, J. W., 45, 119, 260
Grant, B. F., 22
Griffin, A., 22
growth curve modeling, and growth trajectory hypothesis for progression, 223, 227, 230–232
Guttman scale: and analytic variations in progression, 226, 227; and cross-sectional studies, 5; and stages of progression, 271, 272, 280

hallucinogens: and life skills training program, 130; and studies of order of progression, 6
Hawkins, J. D., 22
Hays, R. D., 6
hazard rates: and association of stages of progression, 188, 276; and initiation of alcohol, tobacco, and marijuana, 54–55
heroin: age at onset and progression, 78–79; and basic model of progression, 70–73; and cross-sensitization, 325; and ethnic differences in sequences of progression, 77; and gender differences in sequences of progression, 76, 199–204, 214–216; and life skills training program, 130; and parametric event sequence analysis, 206–213, 218–222; and progression to hard drug use in inner-city New York, 109; race and patterns of progression, 204–206, 214–216; and reinforcement, 342, 351; and sequence of drug involvement, 66, 67
higher-use stage, 37–38
historical variation, and first substance used, 102–109
Hofer, S. M., 45
Holland, S., 22
Hyatt, S. L., 260
hypervigilance, and alcohol use, 300

Indianapolis, and multicommunity-based drug abuse prevention program, 143
inhalants, and substance-specific progression, 117–118
initiation, of drug use: measures of, 48*t*; and parametric event sequence analysis, 218–222; predictors of for adolescent smoking, 164–170; and prevention programs, 124–135; and quasi-independence model, 191–194; and reinforcement, 339; and sequence of drug use progression, 368; and survival analysis of alcohol, tobacco, and marijuana, 52–60. *See also* age of onset
intensity, of drug use: and association, 369; and causality, 370; and developmental trajectories as predictors of drug abuse and dependence, 29–32, 36–37; measures of, 25, 28*t*. *See also* frequency
interdomain behavior sequences, and drug use progression, 225
intraindividual changes and differences, and quasi-independence model, 280
intrapsychic factors, and marijuana as gateway for cocaine, 265

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521783496 - Stages and Pathways of Drug Involvement: Examining the Gateway Hypothesis
Edited by Denise B. Kandel
Index
More information

Jessor, R., 7, 11, 164, 176, 177, 225, 271
Jessor, S. L., 164, 176, 177
Johnson, B., 10, 20–21, 65, 91, 92, 98

Kandel, D. B., 11, 21, 66, 69, 90, 118, 176, 188, 194, 224, 225, 254, 255, 271, 272, 273, 274–275, 276, 277–284
Kansas City, and multicommunity-based drug abuse prevention program, 143
Klein, L. C., 295–296
knock-out mice, 307, 342
Koob, G. F., 11, 297

Labouvie, E., 22, 65, 98
Langeheine, R., 279
latent growth curve models, and analysis of cigarette smoking and drug use progression, 228–232, 237–240, 242–245
Latent Growth Modeling, problem behavior and drug use in adolescents, 173
latent Markov (LM) model, 279
latent states: and latent transition analysis, 259, 262, 266; and mixed Markov latent class model, 277–279
Latent Transition Analysis (LTA): and association of stages of progression, 274, 276, 281–282; and evidence for developmental progression, 119, 227; quasi-independence model compared to, 277–284; and study of alcohol initiation, 256–268; and study of social norms and transitions in substance use, 44, 46–52
Leventhal, A., 90
life event history analysis, and drug use progression, 226
Life Skills Training (LST), 116, 122–135
life style, and risk factors for drug use, 122
linear growth curve model, and distinction between stages of progression and regression, 276
locomotion, and animal models of drug effects, 305–306, 320, 322, 323–324
log linear models: and identification of pathways of progression, 69, 191–222

Mackesy-Amiti, M. E., 20, 91
MacKinnon, D. P., 45
manifest patterns, of drug use, 274
marijuana: and age of first use as predictor of drug abuse or dependence, 26–29; and basic model of progression, 70–73; and behavioral features of progression, 78–87; and diagnostic criteria for drug dependence, 25–26; as gateway for cocaine, 265; and gender differences in sequences of progression, 73–76, 199–204, 214–216; and growth curve modeling of drug use progression, 241–245; and initiation of cocaine, 67, 265–266; and latent transition analysis of alcohol use, 257–268; and life skills training approach to prevention, 125–126, 128, 129–130; and multicommunity-based prevention program, 153; and parametric event sequence analysis, 206–213, 218–222; prevention programs and behavioral influences on use of, 162–164; and progression to hard drug use in inner-city New York, 98–110; race and patterns of progression, 204–206, 214–216; and sensitization, 322; and sequence of drug use progression, 20–21, 225–226; and social norms of acceptability and harm, 42–43, 44, 46–63; and studies of prevention, 120; and substance-specific progression, 117–118; substitutability and progression, 190–191, 196; and transition diagrams, 97–98; and use trajectory as predictor of drug abuse or dependence, 32, 33–38, 265. *See also* cannabinoids; THC
measurement error, and stages of progression, 273–274, 278. *See also* noise; random errors
mechanism, as framework for behavioral science research, 158

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521783496 - Stages and Pathways of Drug Involvement: Examining the Gateway Hypothesis
Edited by Denise B. Kandel
Index
More information

media, and portrayals of drug use, 121, 122
mediational relationship, amphetamine use and multicommunity-based prevention program, 150–154
methodology: and estimation of mediational effects of prevention programs, 141–143; latent transition analysis and alcohol use, 256–260; parameter estimation and model selection for log linear analysis, 198; and quality of evidence for Gateway Hypothesis, 9. *See also* measurement error; regression analysis; selection bias
methylphenidate, and sensitization, 326–328, 329*f*
mixed Markov latent class (MMLC) model, 277–279
Monitoring the Future (Johnston, O'Malley, & Bachman, 1994), 46, 84–85, 129
Moos, R. H., 165
morphine, and animal models: and cross-sensitization, 324, 325; and reward thresholds, 346*f*; and stress, 302
mothers. *See* bonding; parents and parenting
Mover-random mixture model, 279
mover-stayer model, 279
multidisciplinary approaches, 308, 371–372
multiple substances: and developmental progression of drug use, 117; and life skills training approach to prevention, 127, 129
mu opioid receptor, and reinforcement, 342

naloxone: and reward thresholds, 346*f*; and stress, 302
naltrexone, and prevention of relapse in alcoholics, 349
National Household Survey on Drug Abuse (NHSDA), 66, 67–68, 78, 80, 92–94, 95–96*t*, 99–100, 101*f*, 102, 105, 106, 108*t*, 199
National School Lunch/School Breakfast Program, 44
neurobiology, and animal models of addiction, 337–352
neurochemistry, psychostimulants and sensitization, 321. See also dopamine system
neurophysiology, and developmental progressions in drug use, 87
Newcomb, M. D., 224, 225, 270, 272–273
Newton-Raphson algorithm, 198
New York, progression and hard drug use in inner-city, 92–110
nicotine and nicotine dependence: addiction and behavioral effects of, 291; animal models and studies of, 296, 299–301, 305–306, 307, 320, 322, 323; and behavioral features of drug histories associated with progression, 80–82; nicotinic receptors and reinforcement, 341*f*, 344. *See also* cigarettes
NMDA (N-methyl-D-aspartate) receptor, and reinforcement, 343–344
noise, and sequencing and association in initiation of drug use, 189, 214
norms, and transitions, 42–63
Nurmi, J. E., 91

one-directional drug acquisition model, of drug use progression, 248
onset sequence, and concept of stage of drug use, 37–38
operant conditioning paradigms, and economic factors in drug initiation and maintenance, 294
opiates, and animal models: of reinforcement, 342–343, 348, 350; of self-administration, 296, 298, 299, 300, 303, 304, 305–306
opioid antagonists: and reinforcement, 343; and relapse, 349
opioid peptide-containing neurons, and reinforcement, 341*f*
oppositional behavior, and initiation of drug use in adolescents, 176–177
ordering, and increased risk of progression, 25

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521783496 - Stages and Pathways of Drug Involvement: Examining the Gateway Hypothesis
Edited by Denise B. Kandel
Index
More information

Oregon Social Learning Center (OSLC), 175
organicism, and behavioral science research, 159

Pandina, R. J., 22
parametric event sequence analysis: and modeling of sequencing and association, 194–198, 214, 217–222; and patterns of progression, 206–213; and quasi-independence model, 282–284
parents and parenting: and antisocial behavior, 167; and behavioral influences on adolescent drug use and problem behavior, 166, 169, 171, 173–177; and growth curve modeling of cigarette use and progression, 241–245; and social norms of substance use, 53, 61, 62–63. *See also* bonding; family
pathways: definition of in context of progression, 189; of drug involvement, 69, 72*f*, 187–191. *See also* progression; sequencing; systematic pathways
Patterson, G. R., 173–174, 177
Pedersen, W., 22, 36
peers: and behavioral influences on drug use and problem behavior, 160, 165, 169–170, 171, 173–177; and growth curve models of role of cigarettes in drug use progression, 242–245; and social norms of substance use, 53, 62–63, 121. *See also* social context
personal self-management skills, and life skills training program, 123
personal vulnerabilities, and growth curve models of drug use progression, 248. *See also* psychological characteristics and variables
pharmacology: and animal model studies, 295; and characteristics of drug abuse, 320–321. *See also* psychotropic drugs; sedative-hypnotic drugs; *specific drugs*
Pickering, R. P., 22
pituitary adrenal function, and reinforcement, 347
policy, and implications of research on Gateway Hypothesis, 9–10
Popke, E. J., 301
Poulsen, C. S., 279
predictive verification, and behavioral science research, 158
predictors and prediction: ages of onset and sequencing as, 26–29; and developmental trajectories based on age of onset and intensity, 29–38; growth curve modeling and role of cigarettes in drug use progression, 236–237, 239, 244; and influence of behavior, 159; and influences on drug use sequences, 227; of initiation of smoking in adolescents, 164–170
prevention programs: animal models and research on, 293–294, 308; approaches for, 119–124; and association, 369; and behavioral influences on initiation of drug use, 161–164, 178–179; effectiveness of school-based, 115, 120–121, 178–179; effects of on transitions, 130–134; and initiation in early adolescence, 83–84; initiation and escalation of drug use, 124–135; and life skills training, 116, 122–135; and methodological questions on application of Gateway Hypothesis, 141–143; and multicommunity-based program, 143–154; and patterns of developmental progression, 118; research on development of effective, 115–116; social norms and school-based, 61; and tests of Gateway Hypothesis, 8; and theoretical questions on application of Gateway hypothesis, 139–141; and various drug use outcomes, 125–130
problem solving, and life skills training program, 123
progression, in drug use: alcohol, cigarettes, and marijuana in sequence of, 20–21, 98–102, 214–215; and animal models of sensitization, 319–330; and approaches for prevention, 119–135; behavioral

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521783496 - Stages and Pathways of Drug Involvement: Examining the Gateway Hypothesis
Edited by Denise B. Kandel
Index
More information

progression, in drug use (*cont.*)
features of drug histories associated with, 78–87; comparison of various models of, 277–284; conditions for substantiation of stages of, 187–191, 270–271; ethnic differences in, 55, 56, 59, 76–78, 204–206, 215–216; and evidence for developmental sequence, 119; as fundamental issue in research on Gateway Hypothesis, 8–9; gender differences in, 55, 56, 59, 73–76, 199–204, 215; growth curve modeling and context and predictors of, 227; identification of models of, 68–73; inevitability of, 21; models of, 68–73, 191–222; as multidimensional process, 116–118; quasi-independence model and latent transition analysis compared, 277–284; and regression, 276; and sensitization, 322–325, 328–330; and sequences of hard drug use in New York City, 92–110; and sequence proposition in Gateway Hypothesis, 367–368; and stage sequence from licit drugs to marijuana, 206–211; and stage sequence from marijuana to cocaine or heroin, 211–213; and stage sequence for specific substances, 118; variations in concepts and measurement of stages of, 271–277. *See also* sequencing; stage
Project SixTeen, 161–170
protective factors: and academic orientation, 234, 236–238; and bonding to mother, 53–62; and parental support, 234, 236–238; and proactive family management, 53–62; and variation in drug use, 371, 372
psychological characteristics and variables: and animal models, 294–295; and risk factors for drug use, 122; and role of cigarettes in drug use progression, 234, 236–237, 239, 248; and stress-drug relationship in animal models, 302
psychostimulants: and hyperlocomotion, 320; and reinforcement, 340, 342; and sensitization, 321
psychotropic drugs, and drug progression sequence, 368

quasi-independence model: and association of stages of progression, 274–275; and identification of pathways of progression, 69, 191–198; and latent transition analysis, 277–284; and methods of parameter estimation, 198; and parametric event sequence analysis, 282–284

race: and differences in sequences of progression, 76–78, 367; and initiation of marijuana use, 59; and life skills training approach to prevention, 126; and log linear analysis of progression, 204–206, 207*f*, 208–209*t*, 211, 213, 214–222; and progression to hard drug use in inner-city New York, 107*t*. *See also* ethnicity
random errors: and concepts of sequencing and association in initiation of drug use, 189, 214; and latent transition analysis, 268. *See also* measurement error; noise
reductionism, and research on adolescent problems in behavioral sciences, 178
regression analysis: and association of stages of progression, 276; models of and study of multicommunity-based prevention program, 146–149, 150
Reid, J. B., 173–174
reinforcement: and drug dependence, 338–339; and neurobiological substrates, 345–348, 349–351; and neurological mechanisms, 340–344. *See also* addiction
relapse, animal models of, 349, 351, 352
risk factors: accumulation of multiple, 121; for adolescents versus adults, 26, 27*t*, 34–35; and antisocial behavior, 164–165, 167–168, 170; caffeine use and alcohol initiation, 255; and establishment of gateway sequence, 266; and friends' drug use, 234, 236–239, 248–249; and friends' smoking, 166–171; and inadequate

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521783496 - Stages and Pathways of Drug Involvement: Examining the Gateway Hypothesis
Edited by Denise B. Kandel
Index
More information

monitoring or parenting, 165–171; and low family supportiveness, 165, 168–170; measures of, 26, 27*t*; and negative parent–child interactions, 165–171, 240–244; norms as, 52–54, 59–61; ordering as, 25; and peer encouragement of drug use, 240–244, 248–249; and prediction of drug abuse/dependence from use trajectories, 33–34, 36–37; and psychological distress, 234, 236–239, 248. *See also* age of onset; sensitization
Robins, L., 84
R-technique/T-technique factor analysis, 29–30

Satorra, A., 235
Schafer, J. L., 45
Schenk, S., 297
schools: academic failure and initiation of drug use, 172–173, 176–177, 236–237; effectiveness of prevention programs in, 115, 120–121, 178–179; social norms and prevention programs in, 61
Seattle Social Development Project (SSDP), 43–44, 62
sedative-hynoptic drugs, and reinforcement, 343
selection bias, and limitations on establishment of causality, 283–284
self-administration, and animal models for drug use and abuse, 292–293, 296–297, 300, 302, 321, 322, 324, 326
self-report data: progression and hard drug use in inner-city New York, 97–98; and information on drug initiation and maintenance in children, 289, 292
self-selection, and age at onset of drug initiation, 84
sensation seeking traits, 318
sensitization: and animal models of progression, 319–330; and involvement of extended amygdala, 350
sensory gating, 299
sequencing, of drug use: and association, 188–189, 213–216, 270; cigarette smoking and model of, 224–227; ethnic differences in, 76–78, 204–206; gender differences in, 73–76, 199–204; log linear models and differences in, 69, 191–198; and parametric event sequence analysis, 194–198, 206–211, 216–222; as predictor of drug abuse and drug dependence, 26–29; and progression, 20, 201–218, 270; and sequential order of initiation, 187–188. *See also* progression
sexual behavior: and initiation of drug use in adolescents, 172–173, 176–177; sequencing and adolescent development, 367
Single, E., 271
Skrondal, A., 22, 36
smoking. *See* cigarettes
Smolkowski, K., 162
social context: and animal models of drug use and abuse, 304–305; and approaches to prevention, 121, 122; and behavioral features of progression, 87; and behavioral influences on substance use initiation in adolescents, 170–179; and causality, 370–371; and developmental sequences of drug use, 367; and growth curve models of role of cigarettes in drug use progression, 240–249; and latent transition analysis, 265; and progression to hard drug use in inner-city New York, 109; and social influences on drug use, 160–179. *See also* culture; peers; social norms; social skills
Social Development Model, 43
social norms, and transitions in substance use from late childhood to late adolescence, 42–63. *See also* culture; social context
social skills, and life skills training program, 123. *See also* peers; social context
stage, and conditions for progression, 187–191

© Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
0521783496 - Stages and Pathways of Drug Involvement: Examining the Gateway Hypothesis
Edited by Denise B. Kandel
Index
More information

Stepping-Stone Theory, 4
stress, and animal models of drug self-administration, 296–297, 301–304
structural equation modeling (SEM): and analysis of cigarette smoking and drug use progression, 228–232; and life skills training program, 130–132; and multicommunity-based prevention program, 149, 150
Strycker, L. A., 173
sublenticular substantia innominata, and reinforcement, 349–350
subsequent sequencing, and substitutability of substances in drug use initiation, 190
Substance Abuse and Mental Health Services Administration (SAMHSA), 67, 93, 199
substance-specific progression, 117–118
substitutability, and pathways of drug use progression, 190–191, 196, 214
survival analysis, of alcohol, tobacco, and marijuana initiation, 52–60
systematic pathways, of drug use progression, 69, 187. *See also* pathways

THC (tetrahydrocannabinol): and dopamine neurons, 321; and reinforcement, 344, 348; and sensitization, 322–323. *See also* cannabinoids; marijuana
tobacco. *See* cigarettes
trajectories, and dependence, 29–35. *See also* developmental trajectories; pathways
transdisciplinary approach: and animal models for drug use and abuse, 308; and policy issues for research on Gateway Hypothesis, 9–10
transgenic mice, 307
transition diagrams, and analysis of progression, 97–98

unobserved population heterogeneity, 278

van de Pol, F., 279

Welte, J., 6
Werch, C. E., 224
White, H. R., 65
Wiggins, L. M., 279
Windle, M., 6
withdrawal: and negative reinforcement, 345–348, 352; and stress symptoms, 304
Wohlwill, J. F., 19
Wright standardized solution, 235
Wugalter, S. E., 260

Yamaguchi, K., 11, 21, 66, 69, 188, 194, 224, 225, 271, 272, 273, 274–275, 276, 277–284

Zimmerman, M. A., 270

© Cambridge University Press www.cambridge.org